Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by celine.gongora
Group name EquipeCG
Item Type Journal Article
Title [Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine]
Creator Houédé and Milano
Author Nadine Houédé
Author Gérard Milano
Abstract Urothelial carcinoma of the bladder are rare but aggressive tumors with a high metastatic potential. The prognosis of these tumors has not drastically changed over the past 30 years, with an overall survival of less than two years in advanced or metastatic situations. Even though immune checkpoints inhibitors have changed this picture, it is beneficial for less than 30% of patients and there is no reliable biomarkers to identify this specific population of responders. Vinflunine is a vinca-alkaloid that was specifically developed as second line treatment post-platinum. As of today, it is the sole anticancer agent for which clinical trials have been pushed to phase III and that was approved for patients in good conditions. Unfortunately, it has been withdrawn from the list of reimbursed drugs, which impairs its prescription. Based on the results of phase III clinical trials with immunotherapies, this review provides the reader with argumentations in favor of patients' and clinicians' request to reimburse vinflunine for the treatment of advanced or metastatic urothelial carcinoma of the bladder.
Publication Bulletin Du Cancer
Volume 106
Issue 5
Pages 431-435
Date May 2019
Journal Abbr Bull Cancer
Language fre
DOI 10.1016/j.bulcan.2019.02.007
ISSN 1769-6917
Short Title [Care of advanced or metastatic bladder cancer in second line
Library Catalog PubMed
Extra 00000 PMID: 30981463
Tags Bladder cancer, Cancer de vessie, first, Humans, Métastase, Metastases, Neoplasm Metastasis, Neoplasm Staging, review, Second line treatment, Traitement de deuxième ligne, Urinary Bladder Neoplasms, Vinblastine, Vinflunine
Date Added 2019/10/10 - 10:45:00
Date Modified 2019/10/24 - 16:24:31
Notes and Attachments PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés